Inside Theranostics: Decoding the Mechanism of Action

The theranostics is manufactured by attaching an isotope (eg. Yttrium-90 (90Y)) as chloride form into the chelating agent (a chemical structure used to attach the isotope (eg. DOTA) that is bound to the targeting molecule called a ligand. The ligand is specific for the cancer type binding to a target on the surface of the cancer cells in the patient.

This process is known as radiolabelling and performed by a qualified radiochemist in a specialised nuclear medicine radiation facility.